Abstract 5222
Background
Targeted hotspot cancer NGS panels are becoming an integral part of clinical practice for detection of clinically relevant mutations. Tumor mutation burden (TMB) has arisen as a biomarker in the immunotherapy field, challenging established hotspot panels. So far, testing has been steep, limited to whole exome sequencing (WES) or external commercial NGS assays, neither of which are feasible strategies for future local testing. Clinical routine implementation requires development and validation of new, comprehensive tests, able to deal with day-to-day reality in testing labs, such as input DNA quality and amount limitations or turnaround-time restraints.
Methods
We designed a custom NGS assay, VHIO-300, to detect mutations, copy number alterations (CNA), gene fusions, loss-of-heterozygosity and TMB scoring from tumor samples. VHIO-300 is a capture enrichment of over 430 cancer genes, covering enough sequence to allow TMB calculation (≈1.3 Mb), as well as 2 Mb of non-coding genomic regions. Here, we report the analytical and clinical validation procedures. Analytical sensitivity was conducted on positive control DNAs derived from 5 ATCC cell lines comprising 40 SNVs and indels. Clinical samples with WES data were used to determine specificity, sensitivity and robustness. VHIO-300 performance for TMB calling was tested using 50 FFPE-derived tumor specimens compared to scores provided from both WES and Foundation One test.
Results
Panel design was tuned to improve detection of capture-sensitive variants such as indels, that affect relevant genes in cancer like EGFR, BRCA1/2 or KIT, improving analytical sensitivity by two-fold. The VHIO-300 panel achieved 92.5% clinical sensitivity and 99.9% clinical specificity for SNVs and indel calling compared to WES data. CNA achieved 85% sensitivity and 99.6% specificity compared to array comparative genomic hybridization. Several in-silico TMB calculation algorithms were tested with WES data, the most accurate included both synonymous and non-synonymous calls (r2=0.94).
Conclusions
We provide a complete analytical validation of VHIO-300 panel that makes it a convenient choice for clinical laboratories where a comprehensive genome profiling of FFPE tumor samples is required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vall d’Hebron Institute of Oncology.
Funding
Bristol-Meyers Squibb.
Disclosure
A. Oaknin: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: PharmaMar; Advisory / Consultancy: Clovis Oncology; Advisory / Consultancy: Inmunogen ; Advisory / Consultancy: Genmab ; Travel / Accommodation / Expenses: Roche. M. Alsina Maqueda: Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: MSD; Advisory / Consultancy: Servier; Research grant / Funding (institution): Merck. J. Capdevila: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Bayer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Eisai; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Ipsen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Merk; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Sanofi; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen. E. Elez Fernández: Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Roche; Research grant / Funding (institution): Bayer; Honoraria (self), Research grant / Funding (self): Merck Sorono; Honoraria (self), Research grant / Funding (self): Sanofi. T. Macarulla Mercade: Advisory / Consultancy: Roche; Advisory / Consultancy: Bayer; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Servier. J. Carles: Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Johnson & Johnson ; Advisory / Consultancy: MSD Oncology; Advisory / Consultancy: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony: Astellas Pharma; Advisory / Consultancy: AstraZeneca. C. Saura: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Roche; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Puma; Advisory / Consultancy: Sanofi. J.A. Rodon: Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Roche Pharmaceuticals ; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Orion Pharmaceuticals; Advisory / Consultancy: Servier Pharmaceuticals; Advisory / Consultancy: Peptomyc. R. Dienstmann: Advisory / Consultancy: Roche; Research grant / Funding (self): merck. P.G. Nuciforo: Advisory / Consultancy: Bayer; Advisory / Consultancy: Novartis; Advisory / Consultancy: MSD. E. Garralda: Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Leadership role: ESMO Women for Oncology; Non-remunerated activity/ies: ESMO. E. Felip: Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck KGaA; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck Sharp & Dohme; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche. J. Tabernero: Advisory / Consultancy: Foundation Medicine; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: Genentech; Advisory / Consultancy: Chugai; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Novartis; Advisory / Consultancy: Hoffmann-La Roche Ltd; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Servier; Advisory / Consultancy: Symphogen; Advisory / Consultancy: Biocartis; Advisory / Consultancy: Roche Diagnostics; Advisory / Consultancy: Boehringer Ingelheim. A. Vivancos: Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Sysmex; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: Roche; Advisory / Consultancy: Guardant Health; Research grant / Funding (institution): Debio; Research grant / Funding (institution): Cellestia Biotech. All other authors have declared no conflicts of interest.
Resources from the same session
2831 - Interleukin-6 as a Predictive Marker for Early Response to Induction Chemotherapy in Acute Myeloblastic Leukaemia
Presenter: Salah Khallaf
Session: Poster Display session 1
Resources:
Abstract
6014 - Impact of FLT3-ITD mutation on post-transplant outcome of adult AML is modified by the concomitant NPM1 mutation and pre-transplant remission status: A report from Taiwan Bone Marrow Transplant Registry (TBMTR)
Presenter: Su-peng Yeh
Session: Poster Display session 1
Resources:
Abstract
2914 - Efficacy endpoints studied in clinical trials for early-onset leukaemia
Presenter: Dylan Said
Session: Poster Display session 1
Resources:
Abstract
4691 - High triglyceride is a major risk factor of DIC and differentiation syndrome in acute promyelocytic leukemia
Presenter: Tomohiro Yamakawa
Session: Poster Display session 1
Resources:
Abstract
4395 - DREAMM 4: A Phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Presenter: Suzanne Trudel
Session: Poster Display session 1
Resources:
Abstract
2808 - A Phase 1 Study of HMPL-523, a Selective Oral Anti-Spleen Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Nathan Fowler
Session: Poster Display session 1
Resources:
Abstract
4403 - A Phase 1 Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Jonathon Cohen
Session: Poster Display session 1
Resources:
Abstract
3357 - A global patient-driven Facebook study in a very rare sarcoma: Health-related quality of life in Epithelioid Hemangioendothelioma (EHE) patients
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
2475 - Qualitative study of patients’ experiences of living with and beyond a soft tissue sarcoma diagnosis: the impact of sarcoma specialist services
Presenter: Ana Martins
Session: Poster Display session 1
Resources:
Abstract
2640 - Health-related quality of life issues of patients affected by desmoid-type fibromatosis; experiences from two countries
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract